-
Nacuity Pharmaceuticals Announces Positive Data from Clinical Trial Evaluating NPI-001 to Treat Retinitis Pigmentosa Associated with Usher Syndrome
11 Sep 2025 13:00 GMT
… development of NPI-001, including trial … venture arm, the Retinal Degeneration Fund (RD Fund … Drug Designation for RP, which provides seven years of U.S. FDA … Pharmaceuticals, Inc.
Nacuity Pharmaceuticals is a clinical-stage leader in innovative treatments …
-
Efficacy and Safety of Intravitreal Brolucizumab in Chronic Central Serous Chorioretinopathy: A Retrospective Cohort Study
26 Sep 2025 10:57 GMT
… , photoreceptor disruption, outer retinal atrophy, and consequent, often irreversible … , eyes with prior pharmacological treatment directly targeting the choroid … of our patients developed IOI or retinal … of anti-VEGF medications for central serous …
-
Opus Genetics Doses First Patient in Pivotal LYNX-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions
04 Sep 2025 12:00 GMT
… trial evaluating Phentolamine Ophthalmic Solution 0.75% in treating … S. Food and Drug Administration (FDA) and is being … company developing gene therapies for the treatment of … therapy targeting BEST1-related retinal degeneration. Opus Genetics is …
-
A Race Against Blindness Awards Additional $1 Million Grant to Advance Clinical Trial for Sight-Saving Gene Therapy for Bardet-Biedl Syndrome 1 (BBS1)
04 Sep 2025 11:30 GMT
… to support the clinical development of AXV-101, an … , following the recent Clinical Trial Application (CTA) clearance. … with the goal of stopping retinal degeneration in BBS1 patients. “ … funding research and advancing treatments for progressive vision loss …
-
XLRP, RP, and wet AMD trial data slotted for presentation at EURETINA 2025
30 Aug 2025 00:08 GMT
… anti-VEGF drug candidate for the treatment of wet … (XLRP): Phase 2 DAWN trial, preliminary month 9+ results … platform
Focused on the development and commercialization of novel … vision impairment caused by retinal degeneration, Nanoscope announced it will …
-
Researchers develop new form of Omega-3 DHA capable of protecting against Alzheimer’s-related vision loss
29 Aug 2025 14:05 GMT
… — all linked to retinal degeneration and brain dysfunction.
Unlike … synthetic drugs, aligning with critics who argue Big Pharma … drug trials, suppressed natural alternatives and a history of failed treatments … loss is a compelling development in the fight …
-
Treatment Regimens with Ranibizumab in Neovascular Age-Related Macular Degeneration: Real-World Results from the PACIFIC Study Author List
24 Aug 2025 02:52 GMT
… retinal atrophy.2,3 While therapeutic options are limited for the treatment … (B), treatment-naïve patients with treatment regimen “treat and extend … was funded by Novartis Pharma GmbH, Germany.
… design, development and place in therapy. Drug Des Devel …
-
Opus Genetics Announces FDA Clearance of IND Application for Gene Therapy Candidate OPGx-BEST1
18 Aug 2025 12:00 GMT
… company developing gene therapies for the treatment of … and Drug Administration (FDA) has accepted its Investigational New Drug (IND … related IRD. The trial will also explore biological … therapy targeting BEST1-related retinal degeneration. Opus Genetics is …
-
Phase II Trial Demonstrates Vision Gains in Stargardt Disease With MCO-010
15 Aug 2025 19:42 GMT
… trial (NCT05417126) of MCO-010 (sonpiretigene isteparvovec) for the treatment … responses to the Michigan Retinal Degeneration Questionnaire.
In the press … conviction to advance clinical development of MCO-010 in … 3 Clinical Trial of MCO-010 to Treat Stargardt …
-
First FDA-approved treatment for MacTel performed
12 Aug 2025 20:01 GMT
… first and only FDA-approved treatment for adults with … MacTel has “characterized local retinal degeneration that causes the gradual … other than CNTF to treat other neurovascular glial … or nonsteroidal anti-inflammatory drugs (NSAID).
What should …
About
© 1995-2025